Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban for survival and portal hypertension complications in cirrhosis
2014-005523-27Phase 3Terminated
- Sponsor
- IDIBAPS
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of rivaroxaban in Cirrhosis and Portal Hypertension (PH) (2 arms), sponsored by IDIBAPS. Primary endpoints: Transplant-free survival and Survival free of decompensations/complications of portal hypertension. Started Jul 2015; status: terminated.
02
Drugs
rivaroxaban
03
Conditions
CirrhosisPortal Hypertension (PH)
Beyond the preview
Go deeper on 2014-005523-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005523-27.